jRCTs041200072已完成不适用
COVID-19 Prevention of worsening of symptoms in asymptomatic to mild patients by combined use of kakkonto and hochuekkito: Exploratory open-label randomized controlled trial (HKCOV)
未提供0 个研究点目标入组 100 人开始时间: 待定最近更新:
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 100
- 主要终点
- -
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized Controlled Trial
- 干预模型
- Parallel Assignment
- 主要目的
- Prevention Purpose
- 盲法
- Open(masking Not Used)
入排标准
- 年龄范围
- 20age old over 至 No limit（—）
- 性别
- All
入选标准
- •SARS-CoV-2 is positive in nucleic acid detection or antigen test.
- •20years old or over
- •Asymptomatic or mild symptoms.
排除标准
- •Administration of kampo medicine (Juzendaihoto,Ninjinyoueito, Hochuekkito, Seishoekkito, Rikkunshito, Shikunshito, Kihito, Kamikihito) within the last two weeks
- •Persons with a history of hypersensitivity to Hochuekkito or Kakkonto
- •Those who participated in other clinical intervention studies (studies) within 3 months before the start of study drug administration
- •A person who is judged by the principal investigator or the investigator to be inappropriate as a research subject.
- •Those who are pregnant, may be pregnant, or are breastfeeding
结局指标
主要结局
-
The ratio of worsening within 10days after test drug administration
次要结局
- Blood test
- Changes in Kampo findings
- CT findings
- Deterioration rate(28th day)
- Examination of antibodies before and after administration(28 days later)
- Comparison before and after(10-day observation period)
研究者
相似试验
进行中（未招募）
2 期
COVID-19 Prevention of worsening of symptoms in asymptomatic to mild patients by combined use of kakkonto and hochuekkito:Exploratory open-label randomized controlled trialCOVID-19JPRN-jRCTs041200072Ogawa Keiko100
进行中（未招募）
1 期
High dose Vitamin D in Preventing Aggravation of COVID-19SARS-COV-2 positive patientsMedDRA version: 23.0Level: LLTClassification code 10084382Term: Coronavirus disease 2019System Organ Class: 100000004862MedDRA version: 20.0Level: PTClassification code 10050713Term: Vitamin DSystem Organ Class: 10022891 - InvestigationsMedDRA version: 20.0Level: LLTClassification code 10013097Term: Disease aggravationSystem Organ Class: 100000004867EUCTR2020-001793-30-DKCopenhagen University Hospital of Bispebjerg480
已完成
不适用
International ALLIANCE Study of Therapies to prevent progression of COVID-19, a randomized trialCOVID-19Infection - Other infectious diseasesRespiratory - Other respiratory disorders / diseasesACTRN12620000557932AProf Dr Karin Ried446
招募中
1 期
Therapies to prevent progression of COVID-19 in outpatients: The 'Primary Care Australian COVID-19 Therapeutics' (PACT) TrialACTRN12622000386730AProf Dr Karin Ried300
撤回
不适用
International ALLIANCE Study of Therapies to prevent progression of COVID-19, a randomized trial - Stage 2COVID-19Infection - Other infectious diseasesRespiratory - Other respiratory disorders / diseasesACTRN12622000309785AProf Dr Karin Ried200